Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

28.48
+1.234.51%
Pre-market: 32.003.52+12.36%07:32 EDT
Volume:1.33M
Turnover:37.48M
Market Cap:2.31B
PE:-6.22
High:29.05
Open:26.89
Low:26.54
Close:27.25
Loading ...

Beam Therapeutics (BEAM) Gets a Hold from Barclays

TIPRANKS
·
26 Feb

Beam Therapeutics Inc : Jefferies Raises Target Price to $30 From $23

THOMSON REUTERS
·
26 Feb

Beam Therapeutics Reports 2024 Financial Results and Progress

TIPRANKS
·
26 Feb

Beam Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
25 Feb

Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
25 Feb

Beam Therapeutics Swings to Q4 Loss as Revenue Falls

MT Newswires Live
·
25 Feb

Earnings Flash (BEAM) Beam Therapeutics Posts Q4 License and Collaboration Revenue $30.1M, vs. FactSet Est of $17.2M

MT Newswires Live
·
25 Feb

Earnings Flash (BEAM) Beam Therapeutics Posts Q4 Net Loss $1.09 a Share, vs. FactSet Est of $1.23 Loss

MT Newswires Live
·
25 Feb

Beam Therapeutics Q4 2024 GAAP EPS $(1.09) Beats $(1.18) Estimate, Ended Fourth Quarter 2024 with $850.7M in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into 2027

Benzinga
·
25 Feb

Beam Therapeutics Inc: Cash Runway Expected to Support Operating Plans Into 2027

THOMSON REUTERS
·
25 Feb

Beam Therapeutics Q4 Operating Expenses USD 130.104 Million

THOMSON REUTERS
·
25 Feb

Beam Therapeutics Q4 EPS USD -1.09 VS. Ibes Estimate USD -1.2

THOMSON REUTERS
·
25 Feb

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

GlobeNewswire
·
25 Feb

AI Biotech Stocks Tumbled, with HIMS Plunging 17% and TEM Slumping 15%

Tiger Newspress
·
25 Feb

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

GlobeNewswire
·
24 Feb

Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock So Far in 2025

Insider Monkey
·
24 Feb